CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index; 9 of the 17 sources its claims cite were checked for support.
Abstract
BACKGROUND: . METHODS: After conducting preclinical in vitro and in vivo studies, we evaluated the safety and pharmacodynamic effects of single escalating doses of NTLA-2001 in six patients with hereditary ATTR amyloidosis with polyneuropathy, three in each of the two initial dose groups (0.1 mg per kilogram and 0.3 mg per kilogram), within an ongoing phase 1 clinical study. RESULTS: after a single dose. Serial assessments of safety during the first 28 days after infusion in patients revealed few adverse events, and those that did occur were mild in grade. Dose-dependent pharmacodynamic effects were observed. At day 28, the mean reduction from baseline in serum TTR protein concentration was 52% (range, 47 to 56) in the group that received a dose of 0.1 mg per kilogram and was 87% (range, 80 to 96) in the group that received a dose of 0.3 mg per kilogram. CONCLUSIONS: . (Funded by Intellia Therapeutics and Regeneron Pharmaceuticals; ClinicalTrials.gov number, NCT04601051.).
Overview
CoChat Summary
TL;DR
In six patients with hereditary ATTR amyloidosis with polyneuropathy, single intravenous doses of NTLA-2001, a CRISPR-Cas9 lipid nanoparticle therapy, produced dose-dependent reductions in serum TTR protein at day 28 and only mild adverse events. This interim phase 1 study provides early clinical proof of concept for in vivo CRISPR-Cas9 gene editing.
Key findings
- At day 28, mean reduction from baseline in serum TTR protein concentration was 52% (range, 47 to 56) in the 0.1 mg/kg group and 87% (range, 80 to 96) in the 0.3 mg/kg group.
- Adverse events occurred in three of six patients and were all grade 1 (mild); no serious adverse events were observed. One patient had a grade 1 infusion-related reaction, and increased d-dimer levels in five of six patients returned to baseline by day 7.
- Preclinical studies showed durable TTR knockout after a single dose: in primary human hepatocytes, NTLA-2001 had EC50 0.05 to 0.15 nmol/L and EC90 0.17 to 0.67 nmol/L, with ≥93.7% TTR editing and ≥95% reduction in TTR protein production; in cynomolgus monkeys, a single dose of Cyn-LNP at 3 or 6 mg/kg produced maximum whole-liver gene editing of 73% and >94% reduction in serum TTR protein sustained over 12 months.
Methods
- Interim results from two initial dose groups of a two-part, global, phase 1, open-label, multicenter study: six patients with hereditary ATTR amyloidosis with polyneuropathy received a single intravenous dose of NTLA-2001 at 0.1 mg/kg or 0.3 mg/kg (three patients each) between November 2020 and April 2021.
- Key eligibility included age 18 to 80 years, polyneuropathy due to hATTR amyloidosis with or without cardiomyopathy, body weight 50 to 90 kg, and lack of access to approved ATTR treatments; prior TTR stabilizers were permitted after washout.
- Serum TTR protein was measured by validated enzyme-linked immunosorbent assay at baseline and weeks 1, 2, and 4; analyses were descriptive, comparing baseline with day 28 as mean percentage change and range. Preclinical work included primary human hepatocytes, transgenic mice, and cynomolgus monkeys.
Limitations
- The paper states that the study involves a very small number of patients with limited follow-up to date, and that continued serial measurements are planned to confirm durability. It also states that these are interim results from the first two dose groups in an ongoing dose-escalation study.
- Evident from the text: the clinical portion is open-label with no control group, uses descriptive analyses only, reports safety and pharmacodynamic effects through day 28, and does not report clinical outcomes such as disease progression, quality of life, or mortality.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
7 Valid · 1 Not valid · 5 Not checked · 56 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“TTR, which has a normal physiological role in vitamin A transport. 31”
What the sources say
- Supportedcites [31] 31. Müller ML, Butler J, Heidecker B. Emerging therapies in transthyretin amyloidosis - a new wave of hope after years of stagnancy? Eur J Heart Fail 2020; 22: 39-53. source
The Introduction states that TTR physiologically transports retinol-binding protein. The Therapeutic antisense oligonucleotides section links this function to vitamin A levels, supporting the paraphrase that TTR normally plays a role in vitamin A transport. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“but are limited by the requirement for long-term administration to maintain TTR knockdown.”
What the sources say
- Partly supportedcites [12] 12. Adams D, Gonzalez-Duarte A, O'Riordan WD, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med 2018; 379: 11-21. sourceExperimental — accuracy not yet measured
The Trial Design and Regimens section reports patisiran infusions every three weeks for 18 months, and Pharmacodynamics reports sustained TTR reduction during that period. The paper does not establish that long-term administration is required to maintain knockdown after treatment stops, or that this limitation applies to current ATTR treatments generally. (LLM, conf=0.82)
- Not checked — no full text of the sourcecites [13] 13. Adams D, Polydefkis M, GonzálezDuarte A, et al. Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an openlabel extension study. Lancet Neurol 2021; 20: 49-59. source
- Partly supportedcites [14] 14. Solomon SD, Adams D, Kristen A, et al. Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis. Circulation 2019; 139: 431-43. sourceExperimental — accuracy not yet measured
The Methods (Study Design and Treatment; page unavailable) report patisiran infusions every three weeks for 18 months, and the introductory passage describes its reduction of TTR protein. The paper does not establish that long-term administration is required to maintain TTR knockdown or characterize that requirement as a limitation of current ATTR treatments generally. (LLM, conf=0.82)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“More extensive TTR knockdown is associated with greater improvement in neuropathic end points in patients with hATTR polyneuropathy. 12”
What the sources say
- Partly supportedcites [12] 12. Adams D, Gonzalez-Duarte A, O'Riordan WD, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med 2018; 379: 11-21. sourceExperimental — accuracy not yet measured
The Primary End Point section reports a correlation between the degree of TTR reduction and change in mNIS+7, a composite neuropathy measure, at 18 months. The paper reports improvements in other end points, but our copy does not link the extent of knockdown to improvement across those end points. (LLM, conf=0.86)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“circulating TTR is produced almost entirely (>99%) within the liver, 2”
What the sources say
- Partly supportedcites [2] 2. Gertz MA, Benson MD, Dyck PJ, et al. Diagnosis, prognosis, and therapy of transthyretin amyloidosis. J Am Coll Cardiol 2015; 66: 2451-66. sourceExperimental — accuracy not yet measured
The section labeled “Diagnosis and Classification” says TTR is synthesized primarily in the liver, supporting the liver as its main source. It does not give the claimed >99% figure for circulating TTR. No page number is available in our copy. (LLM, conf=0.86)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Inotersen is associated with serious side effects, including glomerulonephritis and decreased platelet counts. 17”
What the sources say
- Supportedcites [17] 17. Gertz MA, Scheinberg M, Waddington-Cruz M, et al. Inotersen for the treatment of adults with polyneuropathy caused by hereditary transthyretin-medi- - ated amyloidosis. Expert Rev Clin Pharmacol 2019; 12: 701-11. source
The Safety and tolerability section (p. 9) reports decreased platelet counts and glomerulonephritis in patients receiving inotersen, including severe cases. The Regulatory affairs section (p. 9) states that the US approval carries a black box warning for increased risks of thrombocytopenia and glomerulonephritis. (LLM, conf=0.94)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
43 more claims · 1 with their cited sources checked
Create a free account to see all 69 claims and every source verdict.
- Probably not a substantial claim. 11
- It may state two separate claims as one. 15
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“which has already lead to investigational new drugs in clinical trials (NCT04601051)”
From Off-target effects in CRISPR/Cas9 gene editing (2023) · cites this paper as Gillmore et al., 2021
The cited source says what the claim attributes to it.
In the citing paper
“Ionizable lipid nanoparticles (LNPs) are a promising non-viral delivery platform for mRNA nanomedicines (13, 14) that have been used to deliver siRNA and CRISPR-based gene editing therapies to the liver in postnatal mouse, non-human primate, and clinical studies with encouraging results (15–18).”
From Ionizable Lipid Nanoparticles for Therapeutic Base Editing of Congenital Brain Disease (2023) · cites this paper as [17]
Citations
Cites
A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116
Development and Applications of CRISPR-Cas9 for Genome Engineering
Hsu, P. D., Lander, E. S., & Zhang, F. (2014) · Cell · doi:10.1016/j.cell.2014.05.010 · Cited by 5,762
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
Adams, D., Gonzalez-Duarte, A., O’Riordan, W. D., Yang, C.-C., Ueda, M., Kristen, A. V., Tournev, I., Schmidt, H. H., Coelho, T., Berk, J. L., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716153 · Cited by 3,047
Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy
Maurer, M. S., Schwartz, J. H., Gundapaneni, B., Elliott, P. M., Merlini, G., Waddington-Cruz, M., Kristen, A. V., Grogan, M., Witteles, R., Damy, T., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1805689 · Cited by 2,857
Bae, S., Park, J., & Kim, J.-S. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu048 · Cited by 2,339
GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases
Tsai, S. Q., Zheng, Z., Nguyen, N. T., Liebers, M., Topkar, V. V., Thapar, V., Wyvekens, N., Khayter, C., Iafrate, A. J., Le, L. P., et al. (2015) · Nature Biotechnology · doi:10.1038/nbt.3117 · Cited by 2,268
Li, H., Yang, Y., Hong, W., Huang, M., Wu, M., & Zhao, X. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0089-y · Cited by 1,715
The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs
Akinc, A., Maier, M. A., Manoharan, M., Fitzgerald, K., Jayaraman, M., Barros, S., Ansell, S., Du, X., Hope, M. J., Madden, T. D., et al. (2019) · Nature Nanotechnology · doi:10.1038/s41565-019-0591-y · Cited by 1,636
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
Benson, M. D., Waddington-Cruz, M., Berk, J. L., Polydefkis, M., Dyck, P. J., Wang, A. K., Planté-Bordeneuve, V., Barroso, F. A., Merlini, G., Obici, L., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716793 · Cited by 1,452
Self-citationCRISPR–Cas9 genome editing induces a p53-mediated DNA damage response
Haapaniemi, E., Botla, S., Persson, J., Schmierer, B., & Taipale, J. (2018) · Nature Medicine · doi:10.1038/s41591-018-0049-z · Cited by 1,264
Cited by
Items 1,301–1,400 of 1,725
Jordan, A. J., Balmforth, C., Craig, N. J., Dhaun, N., Baker, A. H., Dweck, M. R., & Newby, D. E. (2025) · Heart · doi:10.1136/heartjnl-2024-325280 · Cited by 2
Ramesh, B., & Fakoya, A. O. J. (2025) · Cureus · doi:10.7759/cureus.95908 · Cited by 4
“This reduction suggests a significant decrease in amyloidogenic TTR production, potentially slowing or halting disease progression [83].”
Verkuyl, C. E., Belotserkovsky, A., Zerbes, T., Williams, D., Krishnan, M. R., Zhu, S., Grunnesjoe, S., Eid, S., Zhang, C., Zhao, W., et al. (2025) · PLoS ONE · doi:10.1371/journal.pone.0336578 · Cited by 1
Targeting Circular RNAs (circRNAs) in Atherosclerosis Using CRISPR Technology
Nazarudeen, A., Aswathy, V. R., Rauf, A. A., Aswathy, U. V., Chandran, V. R. M., Abhirami, N., Sudhina, S., Chandran, A., & Ayyappan, J. P. (2025) · The Journal of Gene Medicine · doi:10.1002/jgm.70048 · Cited by 1
“In vivo CRISPR-Cas9 editing delivers the system, often using viral vectors like AAV for organ-specific editing, which is suitable for diseases where ex vivo access is challenging, such as liver and eye disorders [107].”
Khan, S., Wittlieb‐Weber, C. A., & Rossano, J. W. (2025) · Current Heart Failure Reports · doi:10.1007/s11897-025-00734-9 · Cited by 1
“Preliminary results demonstrated a dose-dependent reduction in serum TTR with a good safety profile [ 44].”
Outcome Monitoring and Intermediate End Points for Gene Therapy
Kukavica, D., Trancuccio, A., Brooks, G., & Priori, S. G. (2025) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2025.11.042 · Cited by 2
Deconstructing gene therapy in hemophilia for the clinician
Young, G. A. (2025) · Hematology · doi:10.1182/hematology.2025000763 · Cited by 1
Alkhatib, A. M., Alashqar, R., Abdallah, A. W., Abu-Nejim, H., Hammad, A., Khraisat, O., & Abuzaid, A. (2025) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm42609 · Cited by 1
“It was also noted to be dose-dependent reduction in TTR levels; showing a mean reduction of circulating TTR by 51.66% in the group that received a dose of 0.1 mg/kg and a mean reduction of circulating TTR by 86.66% in the group that received a dose of 0.3 mg/kg at 28 days [54].”
InfluentialTargeting transthyretin by one Cas9 variant with superfidelity and broad compatibility
Qi, S., Wei, L., Ding, Z., Zhong, F., Yang, S., Wu, L., Yang, X., Kang, B., Dan, M., Gan, J., et al. (2026) · Science Advances · doi:10.1126/sciadv.adu6505 · Cited by 2
Chrysostomaki, M., Chatzi, D., Kyriakoudi, S. A., Meditskou, S., Μanthou, M. E., Gargani, S., Theotokis, P., & Dermitzakis, I. (2026) · Genes · doi:10.3390/genes17010056 · Cited by 3
“These include oral TTR stabilizers such as acoramidis, and potentially curative CRISPR-Cas9-based gene editing therapies like NTLA-2001, which have shown promising early results in reducing serum TTR levels in human trials [205].”
Matsuki, N., Awaya, T., Endo, J., et al. (2026) · Diseases · doi:10.3390/diseases14010023 · Cited by 1
“In a first-in-human study, NTLA-2001 led to dose-dependent and durable reductions in serum TTR protein levels, with no clinically significant off-target editing or serious adverse events observed [58].”
Chen, Z., Yang, J., Zheng, B., Yang, Y., Qiu, X., Zhou, H., Wang, R., & Xiong, H. (2026) · Angewandte Chemie International Edition · doi:10.1002/anie.202523579 · Cited by 3
Gene-based Therapies for Genetic Cardiomyopathies: Molecular Medicine for Heart Disease
Sharma, S., Sadasivan, C., Yan, Y., & Oudit, G. Y. (2026) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2026.01.055 · Cited by 3
Ma, J., Kong, M., Zhang, L., Dong, G., Xu, Y., Li, P., Wu, W., & Liu, S. (2026) · Animals · doi:10.3390/ani16040596 · Cited by 2
“…newly identified CRISPR gene-editing system characterized by a relatively small protein size (approximately 1033–1093 amino acids), the ability to autonomously process pre-crRNA, and the recognition of flexible PAM sequences, exhibiting high editing efficiency along with enhanced fidelity [16,17].”
Self-citationIonizable lipids as a promising platform for creating mRNA vaccines
Milagina, S. V., & Puchkov, P. A. (2026) · Fine Chemical Technologies · doi:10.32362/2410-6593-2026-21-1-51-72 · Cited by 1
CRISPR in Thalassemia: Global Research Trend Analysis
Saboor, M., Alblooshi, M. J., Alkaabi, A. A., Soozaei, F. R., & Alketbi, M. H. (2026) · Hemoglobin · doi:10.1080/03630269.2026.2634815 · Cited by 1
“In vivo gene editing has also been investigated for Leber congenital amaurosis [9] and transthyretin [10,11].”
Innovative regenerative genetic and nano therapies for diabetes and metabolic disease
Spanorriga, M.-K., Fragoulis, C., Bega, I., Mavromoustakou, K., Gatsouniotis, I., Lontou, S.-P., Dimitriadis, K. S., Aznaouridis, K., Ktenopoulos, N., Thanopoulou, A. C., et al. (2026) · Exploration of Endocrine and Metabolic Diseases · doi:10.37349/eemd.2026.101461 · Cited by 1
Ijjeh, Y., Alsarayreh, N., Alqudah, D. A., Elzogheir, N., Abuhaliema, A., Shomali, M. R., Abuarqoub, A. H., Ahmad, M. I., Abdelghany, S. M., Alkilany, A. M., et al. (2026) · Advanced Therapeutics · doi:10.1002/adtp.202500395 · Cited by 2
“…gRNA delivery, a landmark achievement was published with a greater than 97% reduction in serum transthyretin (TTR) in non-human primates; however, editing mainly was confined to hepatocytes, which further emphasizes the difficult landscape of attaining precise delivery to extrahepatic targets [12].”
Gene-sized editing for the therapy of genetic diseases
Padureanu, T., Cocoş, R., Matache, I., & Bucur, O. (2026) · Functional & Integrative Genomics · doi:10.1007/s10142-026-01823-1 · Cited by 2
“…al. 2022; Zheng et al. 2022; Zhi et al. 2022b; an et al. 2024; Liu et al. 2024 ; Hołubowicz et al. 2025) containing small interfering RNA for the treatment of hereditary TTR-mediated amyloidosis (Hoy 2018), or in CRISPR-based gene editing clinical trials of the same disease (Gillmore et al. 2021).”
Antiviral and Mutagenic Effects of APOBEC Deaminases A3C, A3D, and A3H in a Hepatitis B Virus Model
Karandashov, I., Brezgin, S., Ponomareva, N. I., Tikhonov, A., Chulanov, V. P., Kostyushev, D. S., & Kostyusheva, A. (2026) · Biochemistry (Moscow) · doi:10.1134/s0006297925603326 · Cited by 1
CRISPR and genome editing: precision tools for personalized therapies
Ranga, P. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-40483-2.00047-9 · Cited by 2
Dutta, K., Savard, A., Reshke, R., Taylor, J. A., Armitage, B., Silva, N. M. L. E., Wu, J., Duli, E., Poudel, B., Bellana, K., et al. (2026) · Cell Biomaterials · doi:10.1016/j.celbio.2026.100424 · Cited by 1
Iwan, V., Nadzemova, O., Weiand, M., Zibert, A., Schmidt, H. H., Tepasse, P., Schierwagen, R., Trebicka, J., & Sandfort, V. (2026) · Gene Therapy · doi:10.1038/s41434-026-00611-7 · Cited by 1
Li, Z., Deng, Y., Huo, Y., Nie, T., Wang, S., Li, D., & Yang, G. (2026) · Chemical Engineering Journal · doi:10.1016/j.cej.2026.176417 · Cited by 1
Functional peptide-assisted delivery of CRISPR/Cas9: recent progress on gene editing
Cho, H. M., Ryu, Y. C., Cho, M. K., & Hwang, B. H. (2026) · Biomaterials Science · doi:10.1039/d6bm00231e · Cited by 1
Zhao, S., Huang, S., Li, N., Wang, N., Yu, Z., Liang, X., Yang, Z., & Guo, H. (2026) · ACS Applied Bio Materials · doi:10.1021/acsabm.6c00032 · Cited by 1
From edits to Circuits: Nucleic acid therapeutics for Correcting human disease
Guinn, M. T., Sinenko, I., Ghanta, R. K., & Veiseh, O. (2026) · Materials Today · doi:10.1016/j.mattod.2026.103351 · Cited by 1
Transthyretin and Vitamin A Metabolism: A Review for the Cardiac Amyloidosis Specialist
Brown, D., Modak, V., Altic, A., Zuwayny, A. A., & Tauras, J. M. (2026) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd13050205 · Cited by 2
Cardiac amyloidosis: Current and pipeline of therapies for the nuclear imager
Davis, B., & Masri, A. (2026) · Journal of Nuclear Cardiology · doi:10.1016/j.nuclcard.2026.102727 · Cited by 1
Rongming, L., Yu, C., Cao, P., Wang, H., & Liang, L. (2026) · Springer eBooks · doi:10.1007/978-981-95-3957-4_21 · Cited by 1
Naoe, Y., Fujimoto, N., Makita, Y., Li, D., Inukai, N., & Hotta, A. (2026) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2026.102958 · Cited by 1
“23,63,64 In conclusion, by combining high-sensitivity in silico nomination, unbiased in vitro cleavage mapping, isogenic iPSC WGS with in-del-cluster features, and targeted amplicon sequencing, we present a conservative, scalable path to off-target risk assessment for LNP-delivered CRISPR therapies.”
High-fidelity genome and prime editing enabled by the AI-designed openCRISPR-1
Hwang, H.-Y., Yi, H., Gwon, Y., Jeon, E. J., & Kim, D. (2026) · Genome Medicine · doi:10.1186/s13073-026-01682-2 · Cited by 2
Rewriting hepatic fate: emerging gene therapy strategies for liver disease
Weiskirchen, R. (2026) · Journal of Translational Genetics and Genomics · doi:10.20517/jtgg.2026.36 · Cited by 1
Sophian, A., Sulanjari, D., Normasari, & Harumanto, A. (2026) · Exploration of Drug Science · doi:10.37349/eds.2026.1008162 · Cited by 1
Zhou, X., K, T., Ding, X., Luo, Z., Yin, C., & Lu, Z. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1872028 · Cited by 1
“…(8, 9); the development of next-generation tools such as base editing and prime editing, enabling precise single-nucleotide changes without inducing double-strand breaks (10, 11); and successful in vivo editing in conditions like transthyretin amyloidosis using lipid nanoparticle delivery (12).”
From LNPs to hybrid nanocarriers: development, challenges and redesign of non-viral gene delivery
Wu, W., Wei, Z., & Peng, X. (2026) · Journal of Nanobiotechnology · doi:10.1186/s12951-026-04622-9 · Cited by 3
“…NCT04601051), an LNP co-formulating Cas9 mRNA with a TTR-targeting guide RNA, achieved a mean reduction in serum TTR of approximately 87% at 28 days after a single intravenous infusion in patients with hereditary transthyretin amyloidosis, with knockdown sustained for at least 12 months [11].”
Balancing efficiency, safety, and scalability in therapeutic genome editing delivery
Shaji, N., Firdous, S., Anbazhagan, S. V., Ganesh, R., Kumari, N., & Kumar, V. (2026) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2026.108643 · Cited by 4
Biologics for cardiovascular diseases: from bench to bedside
Sun, X., Wang, X., Jia, R., Tang, J., Zeng, X. Y., Zhao, F., Zeng, F., Huang, N., Li, J., & Cui, K. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02673-w · Cited by 4
Chiou, T. T., Minga, I., Subashchandran, V., Singulane, C. C., Patel, A. R., Zaręba, K. M., Lu, E., Goyal, A., Singh, J., Elliott, M. D., et al. (2026) · European Heart Journal - Cardiovascular Imaging · doi:10.1093/ehjci/jeag170 · Cited by 3
Latheef, A. K. A., Ali, M., Farahat, O., Gourari, F. M., Alqodsi, E. M., & Akawi, N. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1859881 · Cited by 1
Systemic light chain and transthyretin amyloidosis—treatment advancements and future directions
Bianchi, G., Sanchorawala, V., Wechalekar, A. D., Grogan, M. A., Cuddy, S. A. M., & Merlini, G. (2026) · The Lancet · doi:10.1016/s0140-6736(26)00302-8 · Cited by 2
CRISPR in clinical oncology: translational advances from molecular diagnostics to therapeutics
Grigg, S. E., Shembrey, C., Fareh, M., Blombery, P. A., Corn, J. E., Seymour, J. F., & Casan, J. M. L. (2026) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-026-01179-2 · Cited by 5
“LNPs have emerged as the leading non-viral platform for systemic delivery of CRISPR–Cas-based therapeutics, particularly for RNA format payloads, and have demonstrated clinical success in non-malignant disease settings 181,195,196 .”
Ginn, S. L., Doroudian, F., Christina, S., Chan, O. P. Y., Lucas, C. W., Zhu, E., Yang, S. F., Devanapalli, B., Klein, A. H., Scott, S., et al. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.06.044 · Cited by 2
“30,34 Using dual-AAV-mediated gene delivery, we have configured an HITI editing strategy that simultaneously addresses these challenges and evaluated efficacy in the context of OTC deficiency, a therapeutically challenging exemplar metabolic liver disease.”
Yoo, B., Betancourth, D., Cao, M., Karsenty, C. L., Prasca-Chamorro, D., Pham, Q.-K., Zhang, Y., Pendergast, M. A., Sheehan, V., Park, S. H., et al. (2026) · Cell Biomaterials · doi:10.1016/j.celbio.2026.100537 · Cited by 1
Artificial intelligence in the rational design of lipid nanoparticles for mRNA therapeutics
Zhao, H., Xu, J., Gao, X., Zhu, J., & He, Z. (2026) · The Innovation Drug Discovery · doi:10.59717/j.xinn-drugdisc.2026.100006 · Cited by 6
Delivery Systems for Therapeutic Genome Editing: Challenges, Innovations, and Future Perspectives
Yang, M., Song, Y., Wang, Z., Chao, K., Li, L., Zhang, X., Duan, X., Yu, C., Xue, R., & Zhao, J. (2026) · MedComm · doi:10.1002/mco2.70791 · Cited by 5
Noncoding RNAs and the Architecture of Gene Regulation: Focus on Long and Small Regulatory RNAs
Desind, S. Z., Bell, S. K., & Lutz, C. S. (2026) · Wiley Interdisciplinary Reviews - RNA · doi:10.1002/wrna.70051 · Cited by 2
“…successful clinical trials and regulatory ap-provals over the past decade have demonstrated that RNA drugs can achieve prolonged, sustained treatment effects in humans (Adams et al. 2018; Finkel et al. 2017; Paunovska et al. 2022; Polack et al. 2020; Syed 2025 et al. 2021; NCT06128629 , 2023).”
The future of pediatric gene therapy: CRISPR-Cas9, AI, and personalized medicine
Pan, Y., Ding, J., Wang, W., Xu, D., Fan, J., & Zhang, W. (2026) · Pediatric Research · doi:10.1038/s41390-026-05270-3 · Cited by 2
Hu, M.-Y., Hou, X.-Y., Huang, X.-S., Yu, X.-L., Liu, F., & Yang, J. (2026) · Toxics · doi:10.3390/toxics14070625 · Cited by 1
“…(such as liposomal nanoparticles, gold nanoclusters and polymeric complexes) enable liver-specific delivery of sgRNA/Cas9 ribonucleoproteins or exogenous DNA, significantly enhancing editing efficiency while reducing immunogenicity, thereby paving the way for clinical translation [93].”
Quan, A. T. (2026) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2026.102892 · Cited by 2
Critical chemistry manufacturing and controls considerations for mRNA lipid nanoparticle translation
Liu, L., Wang, Y., Gao, H., Ruan, J., Lu, W., Liu, T., Li, X., Zhang, G., & Xiao, Y. (2026) · Discover Nano · doi:10.1186/s11671-026-04864-4 · Cited by 3
“DOTAP-based LNPs have reached early-phase cancer trials [25], while ionizable lipids underpin in vivo CRISPR therapies such as NTLA-2001 [26].”
Non-invasive control of gene editing in vivo by photoswitchable Cas12f and focused ultrasound
Song, D., Malinao, M. G., Wu, X., Jiang, S., Jiang, D., Westberg, M., Su, Y., Cai, S., Lee, D., Repina, N. A., et al. (2026) · Cell · doi:10.1016/j.cell.2026.09.005 · Cited by 1
New treatments for amyloidosis
Onuora, S. (2021) · Nature Reviews Rheumatology · doi:10.1038/s41584-021-00680-5 · Cited by 1
CAQ Corner: Genetic liver disease
Squires, J. E., & Horslen, S. P. (2022) · Liver Transplantation · doi:10.1002/lt.26467 · Cited by 2
CRISPR gene editing: a revolution in progress
Greener, M. (2022) · Prescriber · doi:10.1002/psb.1990 · Cited by 1
Jindal, I., & Wang, X. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01063-1 · Cited by 1
Medical Use of mRNA-Based Directed Gene Delivery
Matin, A., & Forterre, A. V. (2022) · RNA technologies · doi:10.1007/978-3-031-08415-7_5 · Cited by 1
CRISPR Technology - Recent Advances
Chen, Y. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.102156 · Cited by 2
Actualización en el abordaje diagnóstico y terapéutico de la amiloidosis cardiaca por transtirretina
Combarro, M., González-López, E., Martinez–Naharro, A., & Barge‐Caballero, G. (2022) · REC CardioClinics · doi:10.1016/j.rccl.2022.07.006 · Cited by 3
Genome Editing: Moving Toward a New Era of Innovation, Development, and Approval
Bachtarzi, H. (2023) · Human Gene Therapy · doi:10.1089/hum.2022.230 · Cited by 2
Gene Nanovector for Genome Therapy
Ma, D., & Xi, Z. (2023) · Springer eBooks · doi:10.1007/978-981-19-9776-1_60 · Cited by 1
Diagnostik der kardialen Amyloidose
Meier, C., & Yılmaz, A. (2023) · Die Innere Medizin · doi:10.1007/s00108-023-01571-5 · Cited by 1
Tubben, A., Nienhuis, H. L. A., & van der Meer, P. (2023) · European Journal of Heart Failure · doi:10.1002/ejhf.3053 · Cited by 1
“11 , 1 2 Given these promising developments, it is important to gain a comprehensive understanding of the benefits and limitations of tafamidis in different patient groups.”
BackgroundSchäfer‐Korting, M. (2023) · Handbook of experimental pharmacology · doi:10.1007/164_2023_696 · Cited by 3
Understanding and Overcoming Biochemical Diversity in AL Amyloidosis
Morgan, G. J. (2023) · Israel Journal of Chemistry · doi:10.1002/ijch.202300128 · Cited by 1
McGirr, K., Sarkar, S., & Subramanian, K. (2023) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.13078 · Cited by 1
RetractedOligonucleotides and mRNA Therapeutics
Blenke, E. O., Schiffelers, R. M., & Mastrobattista, E. (2024) · Springer eBooks · doi:10.1007/978-3-031-30023-3_13 · Cited by 1
Davydova, Y. D., Kazantseva, A. V., & Хуснутдинова, Э. К. (2024) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro202412403127 · Cited by 1
« ReNAissance » des biothérapies par ARN
Pitard, B., & Pitard, I. (2024) · médecine/sciences · doi:10.1051/medsci/2024079 · Cited by 2
Widespread Impact of Natural Genetic Variations in CRISPR-Cas9 Outcomes
Li, V. R., Wu, T., Tadych, A., Wong, A. K., & Zhang, Z. (2024) · The CRISPR Journal · doi:10.1089/crispr.2024.0020 · Cited by 2
“Recently, researchers conducted a clinical trial targeting ATTR amyloidosis using CRISPR/Cas9-based therapy to inactivate TTR (29).”
BackgroundReflections on “Can AI Understand Our Universe?”
Wang, Y. (2024) · International Journal of Modern Physics D · doi:10.1142/s0218271825400103 · Cited by 2
Cure the Incurable: Update of Treatment in Inherited Neuromuscular Disorders
Yu, C.-H., & Lai, K. (2024) · Acta Neurologica Taiwanica · doi:10.4103/ant.33-4_review · Cited by 1
Technologies for In Utero Stem Cell Targeting
Borges, B., Lum, T., & MacKenzie, T. C. (2025) · Current Stem Cell Reports · doi:10.1007/s40778-025-00243-4 · Cited by 1
“Standard LNP formulations tend to transfect the liver, as demonstrated by the success of current clinical strategies for in vivo editing [ 78], but can have limited tropism for other cell types.”
Intrauterine Fetal Therapy: Past, Current, and Future
Kamel, R. M. A., Soliman, M. M. H., Bagunaid, M. A., Radwan, M. A., Moallem, A. A., Borah, M., & Al-Murad, B. M. (2025) · Open Journal of Obstetrics and Gynecology · doi:10.4236/ojog.2025.153030 · Cited by 1
A CRISPR-Cas13d cancer therapeutic enables selective elimination of uveal melanoma
Stauber, D., Sosnick, L., Ma, Y., Pimcharoen, S., Lawanprasert, A., Murthy, N., Myung, D. J., & Qi, L. S. (2026) · Molecular Therapy Oncology · doi:10.1016/j.omton.2026.201151 · Cited by 6
First Positive Clinical Data for In Vivo Genome Editing in Humans Opens “New Era of Medicine”
Philippidis, A. (2021) · Human Gene Therapy · doi:10.1089/hum.2021.29170.bfs · Cited by 1
Gene Therapy for Huntington's Disease: The Future Is in Gene Editing
Batista, A. R. (2022) · Human Gene Therapy · doi:10.1089/hum.2021.29192.arb · Cited by 1
Applications of CRISPR-Cas System in Tumor Biology
Ma, M., Liu, Y., & Huang, W. (2021) · ONCOLOGIE · doi:10.32604/oncologie.2022.019415 · Cited by 1
In Utero Gene Editing for Inherited Lung Diseases
White, B. M., Morrisey, E. E., & Peranteau, W. H. (2022) · Current Stem Cell Reports · doi:10.1007/s40778-021-00205-6 · Cited by 2
CRISPR Genome Editing: Into the Second Decade
Livshits, G. (2022) · GEN Biotechnology · doi:10.1089/genbio.2022.29015.gli · Cited by 2
“We have started to see that therapeutic promise materializes with clinical proof of concept emerging in indications, including sickle-cell disease (SCD), 3 a form of hereditary amyloidosis, 4 and cancer.”
Cutting a path to effective delivery of genome engineering machinery
Gladka, M. M., & Baker, A. H. (2022) · Cardiovascular Research · doi:10.1093/cvr/cvac034 · Cited by 1
Targeted Therapeutics for Rare Disorders
Keeling, K. M., Leier, A., Bedwell, D. M., Chen, A. T., Kesterson, R. A., Marquez‐Lago, T. T., Müller, U. F., Zhou, J., Popplewell, L. J., & WALLIS, D. E. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-824010-6.00009-5 · Cited by 1
Treatment of Transthyretin Amyloidosis
Mastrocola, F., Nunes, F., & Sgobbi, P. V. (2023) · Springer eBooks · doi:10.1007/978-3-031-17759-0_22 · Cited by 1
Les thérapies géniques en neurologie
de Courssou, J.-B. B., & Deiva, K. (2023) · Pratique Neurologique - FMC · doi:10.1016/j.praneu.2023.08.002 · Cited by 1
Kumar, R., Le, N., Oviedo, F., et al. (2021) · doi:10.33774/chemrxiv-2021-cdmpf · Cited by 1
Outsmarting Delivery Barriers In Vivo : Base Editing via Next-Generation Virus-Like Particles
Wilson, R. C. (2022) · GEN Biotechnology · doi:10.1089/genbio.2022.29012.rwi · Cited by 1
“4 This followed clinical success reported by CRISPR Thera-peutics, which electroporated hematopoietic stem/progenitor cells ex vivo to introduce preformed Cas9 ribonucleo-protein (RNP) to address hemoglobinopa-thies.”
Extracellular Vesicles for Therapeutic RNA Delivery
Murphy, D. E. (2022) · Utrecht University Repository (Utrecht University) · doi:10.33540/1038 · Cited by 1
CRISPR gene editing – what are the possibilities for respiratory medicine?
Harrison, P. T. (2022) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2022.2056021 · Cited by 1
“Given TTA is caused by a buildup of the misfolded TTR protein, the simplest CRISPR editing strategy, use of a single guideRNA (gRNA) to direct Cas9 to cut and disrupt the TTR gene, was used to see if this would lower the levels of circulating TTR protein [3].”
MethodGenetic deletion of HPV E7 oncogene effectively eliminates HPV driven oropharyngeal cancer tumoursPreprint
Idris, A., McMillan, N. A. J., & Ferreira, D. A. (2022) · Research Square · doi:10.21203/rs.3.rs-1743660/v1 · Cited by 1
Lipid nanoparticles for delivery of gene editing components
Kang, D. D., & Dong, Y. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-822425-0.00096-8 · Cited by 1
Kulcsár, P. I., Tálas, A., Ligeti, Z., Tóth, E., Rakvács, Z., Végi, V. L., Krausz, S. L., Huszár, K., & Welker, E. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.08.16.504097 · Cited by 1
A Peptide Barcode Based Approach for Efficient in vivo Screening of RNA Delivery SystemsPreprint
Odunze, U., Rustogi, N., Devine, P., Miller, L., Pereira, S., Vashist, S., Snijder, A., Corkill, D. J., Sabirsh, A., Douthwaite, J. A., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-2386865/v1 · Cited by 1
TESOGENASE, An Engineered Nuclease Editor for Enhanced Targeted Genome IntegrationPreprint
Nam, H., Xie, K., Majumdar, I., Yang, S., Starzyk, J., Lee, D., Shan, R., Li, J., & Wu, H. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.08.28.553855 · Cited by 1
“; https://doi.org/10.1101/2023.08.28.553855 doi: bioRxiv preprint therapeutic approach to treat Transthyretin amyloidosis (ATTR).”
MethodInfluentialcasmini-tool: a comprehensive database for efficient and specific guide RNA design using dCasMINIPreprint
Lopp, S. M., Borrman, T. M., Jha, N., Silvis, M. R., Swan, R., Yang, X., Alvarez, G., Klappenbach, C. M., Liu, Y., Hart, D. J., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.09.17.558168 · Cited by 1
“…as its small size of 529 amino acids (1587bp) allows researchers to package the DNA sequence for dCasMINI fused to a functional peptide or enzymatic domain capable of gene regulation (which we term "modulator"), along with the promoter sequence and guide RNA sequence, into a standard AAV…”
BackgroundMarsiglia, J. D. C., Vaalavirta, K., Knight, E., Nakamura, M., Cong, L., & Hughes, N. W. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.12.13.571376 · Cited by 1
CRISPR-Cas Associated Cells and Animal Mediated Biomedical ModellingPreprint
Nazir, T., Mirza, H. A., & Rao, N. (2024) · Preprints.org · doi:10.20944/preprints202402.0027.v1
Viral delivery of compact CRISPR-Cas12f for in vivo gene editing applicationsPreprint
Sharrar, A. M., Meacham, Z. A., Staples-Ager, J., de Tacca, L. A., Rabuka, D., Collingwood, T. N., & Schelle, M. W. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.02.06.578965 · Cited by 1
Detection and Quantification of Genome Editing Events in Preclinical and Clinical Studies
Falaleeva, M., Tsai, S. Q., Meyer, K. E., & Lu, Y. (2024) · Wiley eBooks · doi:10.1002/9781119852810.ch14 · Cited by 1
Small molecule amyloid disrupters demonstrate therapeutic efficacy for transthyretin amyloidosisPreprint
Yamane, M., Umeda, H., Toyobe, M., et al. (2024) · ChemRxiv · doi:10.26434/chemrxiv-2024-pghmz · Cited by 1
Amplified genome editing by in vivo editor productionPreprint
Ngo, W., Rosas-Rivera, D., Wasko, K. M., Qiu, L., Kang, M. H., Gogna, S., Zeng, J., Hooks, M. T., Wu, J. L. Y., Li, Z., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.13.699115 · Cited by 1
Metadata
- Authors
- Gillmore, J. D., Gane, E., Taubel, J., Kao, J., Fontana, M., Maitland, M. L., Seitzer, J., O’Connell, D., Walsh, K. R., Wood, K., Phillips, J., Xu, Y., Amaral, A., Boyd, A. P., Cehelsky, J. E., McKee, M. D., Schiermeier, A., Harari, O., Murphy, A., Kyratsous, C. A., Zambrowicz, B., Soltys, R., Gutstein, D. E., Leonard, J., Sepp-Lorenzino, L., & Lebwohl, D.
- Affiliations
- University of Auckland (NZ)
- From the National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Hospital (J.D.G., M.F.) and Richmond Pharmacology, St. George’s University of London (J.T.) — both in London; New Zealand Clinical Research (E.G.), University of Auckland (E.G.), and the Department of Neurology, Auckland City Hospital (J.K.) — all in Auckland, New Zealand; Intellia Therapeutics, Cambridge, MA (M.L.M., J.S., D.O., K.R.W., K.W., J.P., Y.X., A.A., A.P.B., J.E.C., M.D.M., A.S., J.L., L.S.-L., D.L.); and Regeneron Pharmaceuticals, Tarrytown, NY (O.H., A.M., C.A.K., B.Z., R.S., D.E.G.).
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-08-05
- Volume
- 385
- Issue
- 6
- Pages
- 493-502
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3177445623
- Cited by
- 1,801
- References
- 35
- Citations by year
- 2026: 349 · 2025: 332 · 2024: 368 · 2023: 336 · 2022: 328 · 2021: 84
- FWCI
- 228.71
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- Regeneron Pharmaceuticals
- Intellia Therapeutics
- Topics
- Health Sciences › Medicine › Internal Medicine › Amyloidosis: Diagnosis, Treatment, Outcomes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Keywords
- transthyretin amyloidosis, hereditary ATTR amyloidosis, CRISPR/Cas9 genome editing, in vivo gene therapy, prealbumin, polyneuropathy, single ascending dose, pharmacodynamics, safety
- MeSH terms
- Gene Editing, RNA, Guide, CRISPR-Cas Systems, Female, Humans, Infusions, Intravenous, Liposomes, Male, Middle Aged, Prealbumin, RNA, Messenger, RNA, Guide, Kinetoplastida, Gene Transfer Techniques, Amyloid Neuropathies, Familial, Nanoparticles, CRISPR-Cas Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-27, under version 3 of the claim definition (prompt extract-v3).
A second model labelled each claim on 2026-09-27 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.



